Therapeutic effect of dendritic cells loaded with a fusion mRNA encoding tyrosinase-related protein 2 and enhanced green fluorescence protein on B16 melanoma

Tumor Biology

Volumn 25, Issue 5-6, 2004, Pages 252-257

  Fukui, Mikiko ^a,b   Nakano Hashimoto, Tomoko ^a   Okano, Kozue ^a   Maruta, Yuichiro ^a   Suehiro, Yutaka ^a   Hamanaka, Yuichiro ^a   Yamashita, Hiroshi ^a   Imai, Kohzoh ^c   Kawano, Michio M ^b   Hinoda, Yuji ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

B16 melanoma; Dendritic cell; Enhanced green fluorescence protein; Messenger RNA; Tyrosinase related protein 2

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; MESSENGER RNA; PROTEIN; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; ENDOSOME; FEMALE; GENE CONSTRUCT; GENETIC CODE; IMMUNOGENETICS; LOADING TEST; LYSOSOME; MELANOMA B16; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 19944428254     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081388     Document Type: Article

References (32)

1. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
2. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-1288.
3. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, Steinman RM: The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class IIpositive lysosomal compartments. J Cell Biol 2000;151:673-684.
4. Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E, Dannull J: Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002;62:5041-5048.
5. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K: Efficient presentation of known HLA class IIrestricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res 2003;63:5587-5594.
6. Amigorena S: Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med 2002;195:F1-3.
7. Rafiq K, Bergtold A, Clynes R: Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002;110:71-79.
8. You Z, Hester J, Rollins L, Spagnoli GC, van der Bruggen P, Chen SY: A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 2001;61:197-205.
9. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
10. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001;98:8809-8814.
11. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002;99:1517-1526.
12. Steitz J, Bruck J, Gambotto A, Knop J, Tuting T: Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther 2002;9:208-213.
13. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR: Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997;186:65-70.
14. Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000;106:1065-1069.
15. Saenz-Badillos J, Amin SP, Granstein RD: RNA as a tumor vaccine: A review of the literature. Exp Dermatol 2001;10:143-154.
16. Son YI, Egawa S, Tatsumi T, Redlinger RE Jr, Kalinski K, Kanto T: A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods 2002;262:145-157.
17. Okano K, Fukui M, Suehiro Y, Hamanaka Y, Imai K, Hinoda Y: Evaluation of an mRNA lipofection procedure for human dendritic cells and induction of cytotoxic T lymphocytes against enhanced green fluorescence protein. Tumor Biol 2003;24:317-324.
18. Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y: Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: Application to antitumor vaccination. J Immunol 2004;172:776-786.
19. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC: Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-459.
20. Calvo PA, Frank DW, Bieler BM, Berson JF, Marks MS: A cytoplasmic sequence in human tyrosinase defines a second class of di-leucinebased sorting signals for late endosomal and lysosomal delivery. J Biol Chem 1999;274:12780-12789.
21. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-532.
22. Le HN, Lee NC, Tsung K, Norton JA: Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J Immunol 2001;167:6765-6772.
23. Poutsiaka DD, Taylor DD, Levy EM, Black PH: Inhibition of recombinant interferon-gamma-induced Ia antigen expression by shed B16 F10 melanoma cell membrane vesicles. J Immunol 1985;134:145-150.
24. Tanaka K, Gorelik E, Watanabe M, Hozumi N, Jay G: Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol Cell Biol 1988;8:1857-1861.
25. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C: Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001;61:1095-1099.
26. Wang RF: The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269-276.
27. Jackson IJ, Chambers DM, Tsukamoto K, Copeland NG, Gilbert DJ, Jenkins NA, Hearing V: A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. EMBO J 1992;11:527-535.
28. Xu Y, Setaluri V, Takechi Y, Houghton AN: Sorting and secretion of a melanosome membrane protein, gp75/TRP1. J Invest Dermatol 1997;109:788-795.
29. Shimizu K, Thomas EK, Giedlin M, Mule JJ: Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001;61:2618-2624.
30. Eggert AO, Becker JC, Ammon M, McLellan AD, Renner G, Merkel A, Brocker EB, Kampgen E: Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol 2002;32:122-127.
31. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D: Immune response to green fluorescent protein: Implications for gene therapy. Gene Ther 1999;6:1305-1312.
32. Rosenzweig M, Connole M, Glickman R, Yue SP, Noren B, DeMaria M, Johnson RP: Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001;97:1951-1959.